New Market Research Report: NRT Smoking Cessation Aids in the US

Recently published research from Euromonitor International, "NRT Smoking Cessation Aids in the US", is now available at Fast Market Research

[ClickPress, Mon Jan 18 2016] Whilst retail value sales growth in 2015 reached 4%, NRT smoking cessation aids is seeing a lacklustre performance due its shrinking customer base. Smoking in the US has declined from 21 of every 100 adults in 2005 to only 18 of every 100 adults. Tobacco products are highly regulated in the US and many state and federal government agencies sponsor antismoking campaigns. A 2013 study sponsored by the CDC estimated that cigarette smoking is responsible for as much as US$170 billion in annual health care spending in the US. Much of this cost is borne by government-sponsored insurance programmes such as Medicare and Medicaid. Restrictions are also expanding, with smoking bans extending to apartments, public housing and cars carrying children. For instance, the city of Santa Monica made all newly occupied apartments non-smoking. Frequent antismoking campaigns such as the CDC’s “Tips From Former Smokers” are meant to connect with smokers on an emotional level and motivate them to cut back and ultimately, quit. The price of cigarettes also acts as a deterrent, as the price of cigarettes in the US is amongst the highest in the world with consistent tax increases. These measures have been successful in reducing the number of US smokers. Whilst current smokers are increasingly receptive to giving up smoking, the overall customer base for NRT products continues to decline, along with the smoking population.

Full Report Details at

Competitive Landscape

The only two major players in NRT smoking cessation aids in the US are GlaxoSmithKline and private label, which together accounted for over 99% of retail value sales in 2015. GlaxoSmithKline is the only major producer of branded NRT products, with its Nicorette brand in gum and lozenges and Nicoderm CQ brand in patches. GlaxoSmithKline has made a strong push into smoking cessation programmes, teaming up with the retailers Walgreen and Walmart in 2013. These programmes leverage in-store and online behavioural support in combination with personalised NRT product recommendations, providing a powerful platform to endorse its brands. However, significant manufacturing disruptions in the first half of 2014 limited sales and allowed private label products to capture share. Although GlaxoSmithKline had the potential to further boost its position in NRT, the FTC required that Novartis divest its Habitrol brand of NRT patches before the consumer health joint venture could be completed.

Industry Prospects

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- NRT Smoking Cessation Aids in Finland
- NRT Smoking Cessation Aids in South Korea
- NRT Smoking Cessation Aids in Hong Kong, China
- NRT Smoking Cessation Aids in Italy
- NRT Smoking Cessation Aids in Belgium

Company: Fast Market Research, Inc.

Contact Name: Bill Thompson

Contact Email:

Contact Phone: 1-413-485-7001

>>Visit website